Overview

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Status:
Active, not recruiting
Trial end date:
2024-05-27
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation